Prognostic role of microRNA-181a/b in hematological malignancies: a meta-analysis.
Prognostic role of microRNA-181a/b in hematological malignancies: a meta-analysis.
复制标题
microRNA-181a/b 在血液恶性肿瘤中的预后作用：荟萃分析。
DOI：
10.1371/journal.pone.0059532
复制
发表时间：
2013
期刊：
影响因子：
3.7
通讯作者：
Wang S
中科院分区：
文献类型：
--
作者：
Lin S;Pan L;Guo S;Wu J;Jin L;Wang JC;Wang S
新的证据表明，miRNAs作为肿瘤抑制基因或癌基因参与了人类的癌症发生，并对癌症患者具有预后价值。近年来，miR-181家族在多种人类癌症中被发现表达异常，并与癌症患者的临床预后密切相关。MiR-181a和miR-181b(miR-181a/b)是该家族中被调查最多的成员。然而，不同研究的miR-181a/b结果并不一致。因此，我们进行了一项荟萃分析来总结现有研究的所有结果，旨在描述miR-181a/b在人类癌症中的预后作用。检索到的文章来自两个主要的在线数据库：PubMed和EMBASE。我们提取并估计了总生存期(OS)的风险比(HRs)，它比较了现有研究患者中miR-181a/b的高和低表达水平。每个单独的HR被用来计算合并的HR。经过严格的筛选和鉴定过程，1252名患者的11项研究被选入最终的荟萃分析。根据研究之间的异质性，选择固定模型或随机模型方法。亚组分析显示，高表达的miR-181a/b可以延长恶性血液病患者的OS，而不是低表达的患者(HR = 0.717，P<；0.0001)。而miR-181a/b在不同肿瘤中的表达与OS无明显相关性(HR = 0.861，p = 0.356)。我们的研究表明，miR-181a/b的表达水平与恶性血液病的OS显著相关，可作为判断患者预后的重要指标。
Emerging evidence has shown that miRNAs participate in human carcinogenesis as tumor suppressors or oncogenes, and have prognostic value for patients with cancers. In recent years, the miR-181 family was found dysregulated in a variety of human cancers and significantly associated with clinical outcome of cancerous patients. MiR-181a and miR-181b (miR-181a/b) were the most investigated members in the family. However, the results of miR-181a/b from different studies were inconsistent. Therefore, we performed a meta-analysis to summarize all the results from available studies, aiming to delineate the prognostic role of miR-181a/b in human cancers. The identified articles were retrieved from the two main on-line databases, PubMed and EMBASE. We extracted and estimated the hazard ratios (HRs) for overall survival (OS), which compared the high and low expression levels of miR-181a/b in patients of the available studies. Each individual HR was used to calculate the pooled HR. Eleven studies of 1252 patients were selected into the final meta-analysis after a strict filtering and qualifying process. Fixed model or random model method was chosen depending on the heterogeneity between the studies. The subgroup analysis showed that high expressed miR-181a/b could prolong OS in patients with hematological malignancies rather than low expression level (HR = 0.717, P<0.0001). But the expression of miR-181a/b was not significantly relative to OS in patients with various cancers (HR = 0.861, p = 0.356). Our study indicates that the expression level of miR-181a/b is significantly associated with OS in hematological malignancies and can be an important clinical prognostic factor for those patients.
登录
查看更多内容
miR-181b 和 miR-21 在接受 S-1/奥沙利铂或多西氟尿苷/奥沙利铂治疗的胃癌患者中的预后意义
影响因子：
3.7
作者：
Jiang J;Zheng X;Xu X;Zhou Q;Yan H;Zhang X;Lu B;Wu C;Ju J
通讯作者：
Ju J
影响因子：
14.9
作者：
Kozomara A;Griffiths-Jones S
通讯作者：
Griffiths-Jones S
影响因子：
2.6
作者：
Choong, Meng Ling;Yang, Henry He;McNiece, Ian
通讯作者：
McNiece, Ian
DOI：
10.1007/s00432-011-1137-3
发表时间：
2012-04-01
影响因子：
3.6
作者：
Bai, Haitao;Cao, Zhongwei;Wang, Chun
通讯作者：
Wang, Chun
影响因子：
14.9
作者：
Griffiths-Jones, S;Bateman, A;Eddy, SR
通讯作者：
Eddy, SR